Immunotherapy in Head and Neck Squamous Cell Cancer.
- Author:
Nerina DENARO
1
;
Marco Carlo MERLANO
Author Information
- Publication Type:Review
- Keywords: Immunotherapy; Tumor Immune Escape; Squamous Cell Carcinoma; Head And Neck; Biomarkers
- MeSH: Biomarkers; Carcinoma, Squamous Cell; Cetuximab; Drug Therapy; Epithelial Cells*; Head and Neck Neoplasms; Head*; Humans; Immunotherapy*; Neck*; Neoplasms, Squamous Cell*; Platinum; Prognosis; Tumor Escape
- From:Clinical and Experimental Otorhinolaryngology 2018;11(4):217-223
- CountryRepublic of Korea
- Language:English
- Abstract: Prognosis in relapsed metastatic head and neck squamous cell cancer (RM-HNSCC) is dismal. Platinum based chemotherapy in combination with Cetuximab is used in first-line setting, while no further validated options are available at progression. Immunotherapy has produced durable clinical benefit in some patients with RM-HNSCC although the premises are several patients are nonresponders. Studies are ongoing to determine predictive factors and the ideal setting/combination of novel immunotherapies. In this paper, we discuss the past and present of immunotherapy in head and neck cancer and provide an up-to-date information regarding the potential ways to improve immunotherapy outcomes in HNSCC.
